MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An alt...
Saved in:
Published in | Medical oncology (Northwood, London, England) Vol. 28; no. 4; pp. 1549 - 1554 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.12.2011
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1357-0560 1559-131X 1559-131X |
DOI | 10.1007/s12032-010-9561-9 |
Cover
Abstract | Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (
P
= 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (
r
= 0.209,
P
= 0.01). Moreover, the same genotype was correlated with lymphocyte number (
r
= 0.269,
P
= 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (
r
= 0.247,
P
= 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL. |
---|---|
AbstractList | Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P=0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r=0.209, P=0.01). Moreover, the same genotype was correlated with lymphocyte number (r=0.269, P=0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r=0.247, P=0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P=0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r=0.209, P=0.01). Moreover, the same genotype was correlated with lymphocyte number (r=0.269, P=0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r=0.247, P=0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL. Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL. Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed ( P = 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes ( r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number ( r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels ( r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL. Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.[PUBLICATION ABSTRACT] |
Author | Penna, G. Musolino, C. Alonci, A. Garufi, A. Cannavò, A. Gerace, D. Allegra, A. Alibrandi, A. Aguennouz, M. |
Author_xml | – sequence: 1 givenname: G. surname: Penna fullname: Penna, G. organization: Division of Hematology, Policlinico G. Martino, University of Messina – sequence: 2 givenname: A. surname: Allegra fullname: Allegra, A. organization: Division of Hematology, Policlinico G. Martino, University of Messina – sequence: 3 givenname: A. surname: Alonci fullname: Alonci, A. organization: Division of Hematology, Policlinico G. Martino, University of Messina – sequence: 4 givenname: M. surname: Aguennouz fullname: Aguennouz, M. organization: Department of Neuroscience, Policlinico G. Martino, University of Messina – sequence: 5 givenname: A. surname: Garufi fullname: Garufi, A. organization: Department of Neuroscience, Policlinico G. Martino, University of Messina – sequence: 6 givenname: A. surname: Cannavò fullname: Cannavò, A. organization: Division of Hematology, Policlinico G. Martino, University of Messina – sequence: 7 givenname: D. surname: Gerace fullname: Gerace, D. organization: Division of Hematology, Policlinico G. Martino, University of Messina – sequence: 8 givenname: A. surname: Alibrandi fullname: Alibrandi, A. organization: Department of Statistics, University of Messina – sequence: 9 givenname: C. surname: Musolino fullname: Musolino, C. email: cmusolino@unime.it organization: Division of Hematology, Policlinico G. Martino, University of Messina |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20496015$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtv1DAUhS1URB_wA9igiA1lYfD1c9wdDFCQipDQILGLHMfpuCR2sJ3F_Hs8TAGpEl35Lr5z7vU5p-goxOAQegrkFRCiXmeghFFMgGAtJGD9AJ2AEBoDg-9HdWZCYSIkOUanOd8QQkFQ_QgdU8K1JCBOUPn87iuGZo7jbopp3vo85eb8kkqlNo0JfbNmnInNy8aH5i222xSDt02F5220u7Kf3fLDTd5cVLzx02xsaWJo8pKtm4vv_OjL7rfVnOJ1iNnnx-jhYMbsnty-Z-jbh_eb9Ud89eXy0_rNFbacsIIdFbpbwcoKySUFbfre9EyajivRDaApd7wbiF2tagr1YEGUpAPpHLBB9qDYGXpx8K2bfy4ul3by9apxNMHFJbe6ZqM0I6tKnt9LApe82lPFK_r8DnoTlxTqP6ofFyC5FhV6dgst3eT6dk5-MmnX_gm-AnAAbIo5Jzf8RYC0-3LbQ7ltLbfdl9vqqlF3NNYXU3wMJRk_3qukB2WuW8K1S_9u_r_oF3k_tKU |
CODEN | MONCEZ |
CitedBy_id | crossref_primary_10_1007_s00580_013_1859_5 crossref_primary_10_3390_antiox13040475 crossref_primary_10_1007_s13277_014_2914_9 crossref_primary_10_1016_j_bios_2012_07_018 crossref_primary_10_1007_s11033_012_1554_7 crossref_primary_10_3390_molecules23010119 crossref_primary_10_1007_s00580_012_1581_8 crossref_primary_10_1007_s12254_018_0446_5 crossref_primary_10_1007_s13277_013_1291_0 crossref_primary_10_3109_10428194_2011_641179 crossref_primary_10_1186_1475_2867_13_46 crossref_primary_10_3109_10428194_2013_800197 crossref_primary_10_1111_ecc_12067 |
Cites_doi | 10.1007/978-1-4615-4811-9_9 10.1016/j.ejphar.2005.10.068 10.1016/0145-2126(94)90085-X 10.1159/000220331 10.1080/10245330310001638974 10.1016/j.clpt.2003.09.012 10.1182/blood-2005-08-3272 10.1016/S0198-8859(02)00426-3 10.1002/ijc.21666 10.1089/dna.2008.0826 10.1182/blood-2008-03-147744 10.1080/10428190701457931 10.1023/A:1013177710941 10.1067/mcp.2001.117412 10.1016/j.leukres.2008.06.008 10.1097/00008571-200106000-00003 10.1016/S0169-409X(02)00064-9 10.1016/j.clpt.2006.07.005 10.1073/pnas.050585397 10.1159/000086579 10.1532/IJH97.E0418 10.1023/A:1026331326648 10.1111/j.1365-2141.2004.05319.x 10.1097/FPC.0b013e3282f82297 10.1080/10428190600881421 10.1007/BF01836067 10.1111/j.1600-0609.2004.00228.x 10.1016/S0959-8049(98)00230-5 10.1111/j.1365-2141.2007.06605.x 10.1016/j.arcmed.2007.02.005 10.1016/j.leukres.2007.04.009 10.1182/blood.V94.6.1848 10.1080/10428190701534473 10.1182/blood.V93.5.1496 10.1007/s12032-010-9456-9 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media, LLC 2010 Springer Science+Business Media, LLC 2011 |
Copyright_xml | – notice: Springer Science+Business Media, LLC 2010 – notice: Springer Science+Business Media, LLC 2011 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7T5 H94 7X8 |
DOI | 10.1007/s12032-010-9561-9 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1559-131X |
EndPage | 1554 |
ExternalDocumentID | 2514239541 20496015 10_1007_s12032_010_9561_9 |
Genre | Journal Article Feature |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 2.D 203 28- 29M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40E 53G 5GY 5RE 5VS 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACCUX ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LLZTM M1P M4Y MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 PZZ Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z82 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ZXP ~A9 ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PUEGO CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7T5 H94 7X8 |
ID | FETCH-LOGICAL-c403t-e259b818c5646219addad36ab475bf1924e4bf0c8803267750762f0be13f6d173 |
IEDL.DBID | 7X7 |
ISSN | 1357-0560 1559-131X |
IngestDate | Fri Sep 05 09:41:24 EDT 2025 Fri Sep 05 14:21:29 EDT 2025 Sat Aug 23 14:07:41 EDT 2025 Mon Jul 21 05:52:50 EDT 2025 Wed Oct 01 02:31:07 EDT 2025 Thu Apr 24 22:52:56 EDT 2025 Fri Feb 21 02:38:20 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | B-chronic lymphocytic leukemia MDR1 Gene polymorphism Prognostic marker |
Language | English |
License | http://www.springer.com/tdm |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c403t-e259b818c5646219addad36ab475bf1924e4bf0c8803267750762f0be13f6d173 |
Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 20496015 |
PQID | 904516495 |
PQPubID | 30753 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_905679308 proquest_miscellaneous_1464507274 proquest_journals_904516495 pubmed_primary_20496015 crossref_primary_10_1007_s12032_010_9561_9 crossref_citationtrail_10_1007_s12032_010_9561_9 springer_journals_10_1007_s12032_010_9561_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20111200 2011-12-00 2011-Dec 20111201 |
PublicationDateYYYYMMDD | 2011-12-01 |
PublicationDate_xml | – month: 12 year: 2011 text: 20111200 |
PublicationDecade | 2010 |
PublicationPlace | Boston |
PublicationPlace_xml | – name: Boston – name: United States – name: Middlesex |
PublicationTitle | Medical oncology (Northwood, London, England) |
PublicationTitleAbbrev | Med Oncol |
PublicationTitleAlternate | Med Oncol |
PublicationYear | 2011 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Van der Holt (CR14) 2006; 80 Kim (CR11) 2005; 114 Kim, Park, Sohn, Lee, Lee (CR17) 2006; 91 Dulucq (CR18) 2008; 112 Hitzl (CR9) 2001; 11 Rochlitz (CR26) 1992; 65 Potocnik, Ravnik-Glavac, Glavac (CR32) 2002; 7 Pawlik, Baskiewicz-Masiuk, Machalinski, Kurzawski, Gawronska-Szklarz (CR35) 2005; 528 Jamroziak (CR25) 2009; 33 CR36 Krajinovic, Labuda, Richier, Karimi, Sinnett (CR31) 1999; 93 Jamroziak (CR29) 2004; 72 Rund, Azar, Shperling (CR28) 1999; 457 Hoffmeyer (CR8) 2000; 97 Hattori (CR30) 2007; 31 Tatari (CR23) 2009; 28 Golapud, Gupta (CR33) 2001; 21 Guillaume (CR27) 2007; 48 Jamroziak, Robak (CR4) 2004; 9 Buda (CR15) 2007; 137 Maggini (CR16) 2008; 18 Hamblin, Davis, Gardiner, Oscier, Stevenson (CR20) 1999; 94 Iyer, Raain (CR2) 1998; 34 Monzo (CR12) 2006; 107 Turgut, Yaren, Kursunluoglu, Turgut (CR22) 2007; 38 Mattews (CR34) 2006; 47 Tsopra, Ziros, Lagadinou, Symeonidis, Kouraklis-Symeonidis, Thanopoulou, Angelopoulou, Vassilakopoulos, Pangalis, Zoumbos (CR37) 2009; 121 Marzolini, Paulus, Buclin, Kim (CR5) 2004; 75 CR21 Kim (CR6) 2001; 70 Fromm (CR3) 2002; 54 Stanulla (CR13) 2005; 81 Wulf (CR1) 1994; 18 Goreva, Grishanova, Mukhin, Domnikova, Lyakhovich (CR24) 2003; 136 Zheng (CR19) 2002; 63 Kim (CR7) 2005; 118 Schaich, Sourcek, Thiede, Ehninger, Ilmer (CR10) 2005; 128 K Jamroziak (9561_CR4) 2004; 9 DH Kim (9561_CR11) 2005; 114 K Jamroziak (9561_CR25) 2009; 33 M Krajinovic (9561_CR31) 1999; 93 C Mattews (9561_CR34) 2006; 47 S Turgut (9561_CR22) 2007; 38 RB Kim (9561_CR6) 2001; 70 RB Kim (9561_CR7) 2005; 118 M Hitzl (9561_CR9) 2001; 11 H Zheng (9561_CR19) 2002; 63 N Guillaume (9561_CR27) 2007; 48 S Hoffmeyer (9561_CR8) 2000; 97 A Pawlik (9561_CR35) 2005; 528 C Marzolini (9561_CR5) 2004; 75 M Schaich (9561_CR10) 2005; 128 S Golapud (9561_CR33) 2001; 21 G Buda (9561_CR15) 2007; 137 OB Goreva (9561_CR24) 2003; 136 9561_CR36 CF Rochlitz (9561_CR26) 1992; 65 B Van der Holt (9561_CR14) 2006; 80 MF Fromm (9561_CR3) 2002; 54 M Monzo (9561_CR12) 2006; 107 G Wulf (9561_CR1) 1994; 18 M Stanulla (9561_CR13) 2005; 81 OA Tsopra (9561_CR37) 2009; 121 K Jamroziak (9561_CR29) 2004; 72 D Rund (9561_CR28) 1999; 457 TJ Hamblin (9561_CR20) 1999; 94 9561_CR21 U Potocnik (9561_CR32) 2002; 7 S Dulucq (9561_CR18) 2008; 112 L Iyer (9561_CR2) 1998; 34 DH Kim (9561_CR17) 2006; 91 V Maggini (9561_CR16) 2008; 18 H Hattori (9561_CR30) 2007; 31 F Tatari (9561_CR23) 2009; 28 1360821 - Ann Hematol. 1992 Dec;65(6):241-6 16103629 - Acta Haematol. 2005;114(2):78-83 17112800 - Clin Pharmacol Ther. 2006 Nov;80(5):427-39 15203864 - Hematology. 2004 Apr;9(2):91-105 15059065 - Eur J Haematol. 2004 May;72(5):314-21 12406646 - Adv Drug Deliv Rev. 2002 Nov 18;54(10):1295-310 18408561 - Pharmacogenet Genomics. 2008 May;18(5):383-9 17488488 - Br J Haematol. 2007 Jun;137(5):454-6 16769591 - Haematologica. 2006 Jun;91(6):848-51 16331627 - Int J Cancer. 2006 May 1;118(9):2195-201 17568669 - Leuk Res. 2007 Dec;31(12):1633-40 14631505 - Bull Exp Biol Med. 2003 Aug;136(2):183-5 10500782 - Adv Exp Med Biol. 1999;457:71-5 11434506 - Pharmacogenetics. 2001 Jun;11(4):293-8 17107902 - Leuk Lymphoma. 2006 Nov;47(11):2308-13 19388849 - DNA Cell Biol. 2009 May;28(5):259-63 20204543 - Med Oncol. 2011 Mar;28(1):265-9 19468203 - Acta Haematol. 2009;121(4):187-95 17701587 - Leuk Lymphoma. 2007 Aug;48(8):1556-60 14749689 - Clin Pharmacol Ther. 2004 Jan;75(1):13-33 17560460 - Arch Med Res. 2007 Jul;38(5):539-44 11503014 - Clin Pharmacol Ther. 2001 Aug;70(2):189-99 10716719 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 18524988 - Blood. 2008 Sep 1;112(5):2024-7 11811787 - J Clin Immunol. 2001 Nov;21(6):420-30 7912754 - Leuk Res. 1994 Jul;18(7):475-84 18639335 - Leuk Res. 2009 Feb;33(2):332-5 10477713 - Blood. 1999 Sep 15;94(6):1848-54 12175731 - Hum Immunol. 2002 Sep;63(9):765-70 11980438 - Cell Mol Biol Lett. 2002;7(1):92-5 10029576 - Blood. 1999 Mar 1;93(5):1496-501 15717687 - Int J Hematol. 2005 Jan;81(1):39-44 15667534 - Br J Haematol. 2005 Feb;128(3):324-32 9893619 - Eur J Cancer. 1998 Sep;34(10):1493-9 16321374 - Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36 16507781 - Blood. 2006 Jun 15;107(12):4871-9 |
References_xml | – volume: 457 start-page: 71 year: 1999 end-page: 75 ident: CR28 article-title: A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4615-4811-9_9 – volume: 528 start-page: 27 year: 2005 end-page: 36 ident: CR35 article-title: Involvement of C3435T and G 2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2005.10.068 – volume: 18 start-page: 475 year: 1994 end-page: 484 ident: CR1 article-title: Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northen blot analysis publication-title: Leuk Res doi: 10.1016/0145-2126(94)90085-X – volume: 91 start-page: 848 year: 2006 end-page: 851 ident: CR17 article-title: The association between multidrug resistance-1 gene polymorphisms and outcomes of allogenic HLA-identical stem cell transplantation publication-title: Haematologica – volume: 121 start-page: 187 year: 2009 end-page: 195 ident: CR37 article-title: Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha publication-title: Acta Haematol doi: 10.1159/000220331 – volume: 9 start-page: 91 year: 2004 end-page: 105 ident: CR4 article-title: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies publication-title: Hematology doi: 10.1080/10245330310001638974 – volume: 93 start-page: 496 year: 1999 end-page: 1501 ident: CR31 article-title: Susceptibility to childhood lymphoblastic leukemia: influence of CYP1a1, CYP2D6, GSTM1 and GSTT1 genetic polymorphism publication-title: Blood – volume: 75 start-page: 13 year: 2004 end-page: 33 ident: CR5 article-title: Polimorphorsms in human MDR1 (P-glycoprotein): recent advances and clinical relevance publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2003.09.012 – volume: 107 start-page: 4871 year: 2006 end-page: 4879 ident: CR12 article-title: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia publication-title: Blood doi: 10.1182/blood-2005-08-3272 – volume: 63 start-page: 765 year: 2002 end-page: 770 ident: CR19 article-title: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in paediatric heart transplant patients publication-title: Him Immunol doi: 10.1016/S0198-8859(02)00426-3 – volume: 118 start-page: 2195 year: 2005 end-page: 2201 ident: CR7 article-title: Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in the novo acute myeloid leukemia publication-title: Int J Cancer doi: 10.1002/ijc.21666 – volume: 28 start-page: 259 year: 2009 end-page: 263 ident: CR23 article-title: Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population publication-title: DNA Cell Biol doi: 10.1089/dna.2008.0826 – volume: 112 start-page: 2024 year: 2008 end-page: 2027 ident: CR18 article-title: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia publication-title: Blood doi: 10.1182/blood-2008-03-147744 – volume: 48 start-page: 1468 year: 2007 end-page: 1469 ident: CR27 article-title: Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia publication-title: Leuk Lymphoma doi: 10.1080/10428190701457931 – volume: 21 start-page: 420 year: 2001 end-page: 430 ident: CR33 article-title: Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival publication-title: J Clin Immunol doi: 10.1023/A:1013177710941 – volume: 70 start-page: 189 year: 2001 end-page: 199 ident: CR6 article-title: Identification of functionally variant MDR1 alleles among European Americans and African Americans publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2001.117412 – volume: 94 start-page: 1848 year: 1999 end-page: 1854 ident: CR20 article-title: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia publication-title: Blood – volume: 33 start-page: 332 year: 2009 end-page: 335 ident: CR25 article-title: Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma publication-title: Leuk Res doi: 10.1016/j.leukres.2008.06.008 – ident: CR21 – volume: 11 start-page: 293 year: 2001 end-page: 298 ident: CR9 article-title: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells publication-title: Pharmacogenetics doi: 10.1097/00008571-200106000-00003 – volume: 7 start-page: 92 year: 2002 end-page: 95 ident: CR32 article-title: Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability publication-title: Cell Mol Biol Lett – volume: 54 start-page: 1295 year: 2002 end-page: 1310 ident: CR3 article-title: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(02)00064-9 – volume: 80 start-page: 427 year: 2006 end-page: 439 ident: CR14 article-title: ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.07.005 – volume: 97 start-page: 3473 year: 2000 end-page: 3478 ident: CR8 article-title: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.050585397 – volume: 114 start-page: 78 year: 2005 end-page: 83 ident: CR11 article-title: Multidrug resistance as a potential prognostic indicator in acute myeoid leukemia with normal karyotypes publication-title: Acta Haematol doi: 10.1159/000086579 – volume: 81 start-page: 39 year: 2005 end-page: 44 ident: CR13 article-title: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia publication-title: Int J Hematol doi: 10.1532/IJH97.E0418 – volume: 136 start-page: 183 year: 2003 end-page: 185 ident: CR24 article-title: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms publication-title: Bull Exp Biol Med doi: 10.1023/A:1026331326648 – volume: 128 start-page: 324 year: 2005 end-page: 332 ident: CR10 article-title: MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2004.05319.x – volume: 18 start-page: 383 year: 2008 end-page: 389 ident: CR16 article-title: MDR1 diplotypes as prognostic markers in multiple myeloma publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282f82297 – volume: 47 start-page: 2308 year: 2006 end-page: 2313 ident: CR34 article-title: MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVh genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia publication-title: Leuk Lymph doi: 10.1080/10428190600881421 – ident: CR36 – volume: 65 start-page: 241 year: 1992 end-page: 246 ident: CR26 article-title: PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia publication-title: Ann Hematol doi: 10.1007/BF01836067 – volume: 72 start-page: 314 year: 2004 end-page: 321 ident: CR29 article-title: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibly and clinical outcome of childhood acute lymphoblastic leukemia publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2004.00228.x – volume: 34 start-page: 1493 year: 1998 end-page: 1499 ident: CR2 article-title: Pharmacogenetics and cancer chemotherapy publication-title: Eur J Cancer doi: 10.1016/S0959-8049(98)00230-5 – volume: 137 start-page: 454 year: 2007 end-page: 456 ident: CR15 article-title: MDR1 polymorphism influences the outcome of multiple myeloma patients publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2007.06605.x – volume: 38 start-page: 539 year: 2007 end-page: 544 ident: CR22 article-title: MDR1 C3435T polymorphism in patients with breast cancer publication-title: Arch Med Res doi: 10.1016/j.arcmed.2007.02.005 – volume: 31 start-page: 1633 year: 2007 end-page: 1640 ident: CR30 article-title: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia publication-title: Leuk Res doi: 10.1016/j.leukres.2007.04.009 – volume: 114 start-page: 78 year: 2005 ident: 9561_CR11 publication-title: Acta Haematol doi: 10.1159/000086579 – volume: 137 start-page: 454 year: 2007 ident: 9561_CR15 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2007.06605.x – volume: 33 start-page: 332 year: 2009 ident: 9561_CR25 publication-title: Leuk Res doi: 10.1016/j.leukres.2008.06.008 – volume: 7 start-page: 92 year: 2002 ident: 9561_CR32 publication-title: Cell Mol Biol Lett – volume: 121 start-page: 187 year: 2009 ident: 9561_CR37 publication-title: Acta Haematol doi: 10.1159/000220331 – volume: 107 start-page: 4871 year: 2006 ident: 9561_CR12 publication-title: Blood doi: 10.1182/blood-2005-08-3272 – volume: 63 start-page: 765 year: 2002 ident: 9561_CR19 publication-title: Him Immunol doi: 10.1016/S0198-8859(02)00426-3 – volume: 94 start-page: 1848 year: 1999 ident: 9561_CR20 publication-title: Blood doi: 10.1182/blood.V94.6.1848 – volume: 118 start-page: 2195 year: 2005 ident: 9561_CR7 publication-title: Int J Cancer doi: 10.1002/ijc.21666 – volume: 18 start-page: 383 year: 2008 ident: 9561_CR16 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282f82297 – volume: 136 start-page: 183 year: 2003 ident: 9561_CR24 publication-title: Bull Exp Biol Med doi: 10.1023/A:1026331326648 – volume: 112 start-page: 2024 year: 2008 ident: 9561_CR18 publication-title: Blood doi: 10.1182/blood-2008-03-147744 – volume: 21 start-page: 420 year: 2001 ident: 9561_CR33 publication-title: J Clin Immunol doi: 10.1023/A:1013177710941 – volume: 70 start-page: 189 year: 2001 ident: 9561_CR6 publication-title: Clin Pharmacol Ther doi: 10.1067/mcp.2001.117412 – volume: 457 start-page: 71 year: 1999 ident: 9561_CR28 publication-title: Adv Exp Med Biol doi: 10.1007/978-1-4615-4811-9_9 – ident: 9561_CR36 – volume: 91 start-page: 848 year: 2006 ident: 9561_CR17 publication-title: Haematologica – volume: 65 start-page: 241 year: 1992 ident: 9561_CR26 publication-title: Ann Hematol doi: 10.1007/BF01836067 – volume: 128 start-page: 324 year: 2005 ident: 9561_CR10 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2004.05319.x – volume: 72 start-page: 314 year: 2004 ident: 9561_CR29 publication-title: Eur J Haematol doi: 10.1111/j.1600-0609.2004.00228.x – volume: 18 start-page: 475 year: 1994 ident: 9561_CR1 publication-title: Leuk Res doi: 10.1016/0145-2126(94)90085-X – volume: 75 start-page: 13 year: 2004 ident: 9561_CR5 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2003.09.012 – volume: 47 start-page: 2308 year: 2006 ident: 9561_CR34 publication-title: Leuk Lymph doi: 10.1080/10428190600881421 – volume: 34 start-page: 1493 year: 1998 ident: 9561_CR2 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(98)00230-5 – volume: 9 start-page: 91 year: 2004 ident: 9561_CR4 publication-title: Hematology doi: 10.1080/10245330310001638974 – volume: 97 start-page: 3473 year: 2000 ident: 9561_CR8 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.050585397 – volume: 48 start-page: 1468 year: 2007 ident: 9561_CR27 publication-title: Leuk Lymphoma doi: 10.1080/10428190701534473 – volume: 528 start-page: 27 year: 2005 ident: 9561_CR35 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2005.10.068 – volume: 93 start-page: 496 year: 1999 ident: 9561_CR31 publication-title: Blood doi: 10.1182/blood.V93.5.1496 – volume: 31 start-page: 1633 year: 2007 ident: 9561_CR30 publication-title: Leuk Res doi: 10.1016/j.leukres.2007.04.009 – volume: 11 start-page: 293 year: 2001 ident: 9561_CR9 publication-title: Pharmacogenetics doi: 10.1097/00008571-200106000-00003 – volume: 54 start-page: 1295 year: 2002 ident: 9561_CR3 publication-title: Adv Drug Deliv Rev doi: 10.1016/S0169-409X(02)00064-9 – volume: 28 start-page: 259 year: 2009 ident: 9561_CR23 publication-title: DNA Cell Biol doi: 10.1089/dna.2008.0826 – volume: 38 start-page: 539 year: 2007 ident: 9561_CR22 publication-title: Arch Med Res doi: 10.1016/j.arcmed.2007.02.005 – ident: 9561_CR21 doi: 10.1007/s12032-010-9456-9 – volume: 81 start-page: 39 year: 2005 ident: 9561_CR13 publication-title: Int J Hematol doi: 10.1532/IJH97.E0418 – volume: 80 start-page: 427 year: 2006 ident: 9561_CR14 publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.07.005 – reference: 10500782 - Adv Exp Med Biol. 1999;457:71-5 – reference: 16331627 - Int J Cancer. 2006 May 1;118(9):2195-201 – reference: 15717687 - Int J Hematol. 2005 Jan;81(1):39-44 – reference: 16321374 - Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36 – reference: 17107902 - Leuk Lymphoma. 2006 Nov;47(11):2308-13 – reference: 14749689 - Clin Pharmacol Ther. 2004 Jan;75(1):13-33 – reference: 17112800 - Clin Pharmacol Ther. 2006 Nov;80(5):427-39 – reference: 16769591 - Haematologica. 2006 Jun;91(6):848-51 – reference: 9893619 - Eur J Cancer. 1998 Sep;34(10):1493-9 – reference: 12175731 - Hum Immunol. 2002 Sep;63(9):765-70 – reference: 20204543 - Med Oncol. 2011 Mar;28(1):265-9 – reference: 19388849 - DNA Cell Biol. 2009 May;28(5):259-63 – reference: 17488488 - Br J Haematol. 2007 Jun;137(5):454-6 – reference: 10029576 - Blood. 1999 Mar 1;93(5):1496-501 – reference: 17568669 - Leuk Res. 2007 Dec;31(12):1633-40 – reference: 10477713 - Blood. 1999 Sep 15;94(6):1848-54 – reference: 7912754 - Leuk Res. 1994 Jul;18(7):475-84 – reference: 16103629 - Acta Haematol. 2005;114(2):78-83 – reference: 11980438 - Cell Mol Biol Lett. 2002;7(1):92-5 – reference: 18408561 - Pharmacogenet Genomics. 2008 May;18(5):383-9 – reference: 14631505 - Bull Exp Biol Med. 2003 Aug;136(2):183-5 – reference: 11503014 - Clin Pharmacol Ther. 2001 Aug;70(2):189-99 – reference: 12406646 - Adv Drug Deliv Rev. 2002 Nov 18;54(10):1295-310 – reference: 17560460 - Arch Med Res. 2007 Jul;38(5):539-44 – reference: 18524988 - Blood. 2008 Sep 1;112(5):2024-7 – reference: 11811787 - J Clin Immunol. 2001 Nov;21(6):420-30 – reference: 15667534 - Br J Haematol. 2005 Feb;128(3):324-32 – reference: 17701587 - Leuk Lymphoma. 2007 Aug;48(8):1556-60 – reference: 11434506 - Pharmacogenetics. 2001 Jun;11(4):293-8 – reference: 15203864 - Hematology. 2004 Apr;9(2):91-105 – reference: 15059065 - Eur J Haematol. 2004 May;72(5):314-21 – reference: 1360821 - Ann Hematol. 1992 Dec;65(6):241-6 – reference: 18639335 - Leuk Res. 2009 Feb;33(2):332-5 – reference: 19468203 - Acta Haematol. 2009;121(4):187-95 – reference: 10716719 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8 – reference: 16507781 - Blood. 2006 Jun 15;107(12):4871-9 |
SSID | ssj0021529 |
Score | 2.0294774 |
Snippet | Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous... |
SourceID | proquest pubmed crossref springer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1549 |
SubjectTerms | Aged ATP Binding Cassette Transporter, Sub-Family B ATP-Binding Cassette, Sub-Family B, Member 1 - genetics Biomarkers, Tumor - genetics CD38 antigen Cell Separation Female Flow Cytometry Genes, Immunoglobulin Heavy Chain Genetic Predisposition to Disease Genotype Hematology Humans Immunoglobulin Variable Region - genetics Internal Medicine Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Leukemia, Lymphocytic, Chronic, B-Cell - pathology Male Medicine Medicine & Public Health Neoplasm Staging Oncology Original Paper Pathology Polymerase Chain Reaction Polymorphism, Single Nucleotide Prognosis |
SummonAdditionalLinks | – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVkJcoLyXtshIHHjIVTZ-ZMOtLX0ItBzQViqnKHZssWo3WeHksPx6xs5jBaVIvUXKxB7b45n5MuMxwBv0CQoW5T5TLTWUW2np1HJGhVCGxwZ99gAUZ1_l2Tn_fCEuunPcrs9270OSQVNvDrv5y76pD976w5g0vQtbwuOTEWwdnH7_cjzgLDRJacBZIqFo34dg5r8a-dMcXfMxr8VHg9k5eQjznuE22-Ryv6nVvv71Vy3HW45oGx50big5aOXmEdwx5WO4N-sC7U-gnn36RidkVV2tlxUuxcItHXl7GsskmZO8LMgRQw9o_o4sSnJIdVthlyDx6kel17V_Ns2lWS7yj0hO2rOYpCqJa1xIpAk5uevQlE8RKyu3cE_h_OR4fnRGuwsaqOYRq6lB7KTQ4mshuUTVh7oyL5jMFU-Esh7aGa5spFFHMM8g-p4ytpEyE2ZlMUnYMxiVVWleAGGsiA1TKo6t5aLQuW8zFaqQWtmpnI4h6tcp0131cn-JxlW2qbvsZzPD2cz8bGbpGN4Pn6za0h3_I97pFz_rdrHLUl98x7MxhtfDW9x-PqaSl6ZqnEdOHIeF2H4M5AaaFIUQ1WCEg3jeitXAT4wADSExdvChF5FN9zcy-_JW1DtwP_wIDzk4uzCqfzZmDz2pWr3qds5vOBQPxQ priority: 102 providerName: Springer Nature |
Title | MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis |
URI | https://link.springer.com/article/10.1007/s12032-010-9561-9 https://www.ncbi.nlm.nih.gov/pubmed/20496015 https://www.proquest.com/docview/904516495 https://www.proquest.com/docview/1464507274 https://www.proquest.com/docview/905679308 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1559-131X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0021529 issn: 1357-0560 databaseCode: AFBBN dateStart: 19970301 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1559-131X dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0021529 issn: 1357-0560 databaseCode: 7X7 dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1559-131X dateEnd: 20171231 omitProxy: true ssIdentifier: ssj0021529 issn: 1357-0560 databaseCode: BENPR dateStart: 19970301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1559-131X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0021529 issn: 1357-0560 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1559-131X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0021529 issn: 1357-0560 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1RT9swELYYvPAyMcG2AquMxAPbZC2NHafhBRUoICbQhFqpPEWxY4sKSMqcPvTf785JU00InhIlTuycz3f35c53hByCTZDzIMNItcQwYaVlfSs4iyJlRGjAZvdA8eZWXo3F9SSaNLE5rgmrXMpEL6jzUuM_8l8JJkKRYM6fzF4YFo1C52pTQeMD2eiBpYJMHU9WeAtUU-LxVhQz0POtU9PvnMPK4Qw9wbizkyX_q6VXtuYrP6lXPxdb5GNjN9JBPdGfyJoptkl1c37HenRWPgGCB4JN3bOjR5ehjOMRzYqcnnGwU0bf6bSgp0zXeXApNJ49lHpR4bmZP5rnaXYMzWm9Y5KWBXVz58NdfOTswr8KA7mK0k3dDhlfDEdnV6wpo8C0CHjFDCAcBXpZR1JIEFAg0bKcy0yJOFIWAZgRygYaVjLHAYKFKEMbKNPjVua9mH8m60VZmK-Ecp6HhisVhtaKKNcZvjOJVC61sn3Z75BgScVUNznGsdTFU7rKjoyET4HwKRI-TTrkR_vIrE6w8V7jveXUpM1ac2nLGR1y0N6FRYKej6ww5dwhvhHwWYDAO4S-0SYBFgFhFcBHfKknvR1PCDAKgCt08HPJBavu3xzs7ruD3SOb_ve0j4zZJ-vV37n5BvZNpbqei7tkY3B5_3sIx9Ph7Z87uDoOB_8AWKn2-A |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-N8QAvCMRXGQwjgcSHLNLYcZpJ0wQbo2PrHlAn9S2LE1tUrEnBqVD_KP5H7pwmFZq2t71FiuPY5zvf73znO4DXiAkKEWQUqZYYLq2yfGCl4FGkjQwNYnZvKI5O1fBMfptEkw34296FobDKdk_0G3VR5XRG_jGhRCgK4fze_BenolHkXG0raDRccWyWf9Bic7tHB7i8b8Lw8Mt4f8hXRQV4LgNRc4N4X6OWyiMlFYoryndWCJVpGUfakjlipLZBjnyNyCZGhYrbhQ206Qurin4ssN9bcFuKQFKq_niytu9QFSbevotijriic6L6m3pUqZyT55lukvLkfzV4Cdte8st6dXd4H-6tcCr71DDWA9gw5UOoRwffeZ_Nq4vlrMIFmrqZY2-_0gTGLCsLti8QF43fsWnJPvO8ybvLsPH8R5Uva3o2i59mNs12sDlrbmiyqmRu4Xx4jY_UXfquKHCsrNzUPYKzG6HwY9gsq9I8BSZEERqhdRhaK6Miz6jPJNKFyrUdqEEPgpaKab7KaU6lNS7SdTZmInyKhE-J8GnSg_fdJ_Mmocd1jbfapUlXsu3SjhN78Kp7i0JJnpasNNXCkT0lcVpo8feAXdEmQRbBzTHASTxpFr0bT4hmGxrK-IMPLResf3_lYJ9dO9iXcGc4Hp2kJ0enx1tw1x-N-6ic57BZ_16YF4itar3tOZrB-U2L0D-D6y5u |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3raxQxEA-1gvhFFF9nfURQ8EHo3uaxt4KI9jxba4vIFe7buskmeNjbPc0ecn-a_50z2cchpf3WbwubzSaTmcz8MpMZQp6BTVDwKMdItdQy4ZRjIyc4k1JbEVuw2QNQPDpW-yfi80zOtsjf7i4MhlV2e2LYqIvK4Bn5boqJUBSY87uujYr4Op68W_5iWEAKHa1dNY2GQw7t-g-gN__2YAxL_TyOJx-ne_usLTDAjIh4zSzY_ho0lpFKKBBdkPW84CrXIpHaITSxQrvIAI-DlZOAcoWtw0XaDrlTxTDh0O8VcjXhgmM0WTLbYD1Qi2nAejJhYGP0DtVwaw-rljP0QuOtUpb-rxLP2LlnfLRB9U1ukhutzUrfN0x2i2zZ8japj8bf2JAuq9P1ooLFmvuFpy8-4QSmNC8LugfjldOXdF7SD8w0OXgpNF7-qMy6xme7-mkX8_wNNKfNbU1aldSvfAi1CVG769AVBpGVlZ_7O-TkUih8l2yXVWnvE8p5EVuudRw7J2RhcuwzlbpQRruRGg1I1FExM21-cyyzcZptMjMj4TMgfIaEz9IBedV_smySe1zUeKdbmqyVc5_1XDkgT_u3IKDodclLW608YisB0wL0PyD0nDYpsAhslBFM4l6z6P14YoBwAJrhB687Ltj8_tzBPrhwsE_INRCe7MvB8eEOuR5OyUOAzkOyXf9e2UdgZtX6cWBoSr5ftgT9A_OtMqk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MDR-1+polymorphisms+%28G2677T+and+C3435T%29+in+B-chronic+lymphocytic+leukemia%3A+an+impact+on+susceptibility+and+prognosis&rft.jtitle=Medical+oncology+%28Northwood%2C+London%2C+England%29&rft.au=Penna%2C+G&rft.au=Allegra%2C+A&rft.au=Alonci%2C+A&rft.au=Aguennouz%2C+M&rft.date=2011-12-01&rft.issn=1357-0560&rft.eissn=1559-131X&rft.volume=28&rft.issue=4&rft.spage=1549&rft.epage=1554&rft_id=info:doi/10.1007%2Fs12032-010-9561-9&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1357-0560&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1357-0560&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1357-0560&client=summon |